11 results about "Enolase" patented technology

To provide an estimation method for estimating the amount of marker proteins in the stratum corneum. [Solution] Identify one or more cell regions, stratified exfoliation regions, and single-cell regions in the stratum corneum image. A marker protein quantity estimation method that estimates the amount of marker proteins in the stratum corneum from stratum corneum images based on the correlation between the obtained stratum corneum parameters as explanatory variables and one of the following as the dependent variable: Enolase-1 quantity, FABP5 quantity, or Polyamine quantity.

The invention belongs to the technical field of bioinformatics and medical detection, and particularly relates to a marker combination for neuroblastoma (NB) noninvasive risk level grading, a prediction model, a prediction method and application thereof. The marker combination is used for determining the sex, determining whether the month age is greater than 18 months, determining whether plasma MYCN is amplified, determining whether tumors are metastatic, and determining the content of neuron-specific enolase and lactic dehydrogenase; a machine learning algorithm is used for constructing an NB noninvasive risk degree grading prediction model, the comprehensive performance of the random forest model is optimal, the area value under a subject working characteristic curve reaches 0.956, the sensitivity is 92.9%, the specificity is 82.1%, the accuracy rate is 87.5%, the Kappa value is 0.75, the F1 score is 0.881, and NB middle and low risk patients and NB high risk patients can be effectively distinguished; the NB non-invasive risk level grading prediction model constructed by the invention can quickly, accurately and non-invasively perform NB risk level grading, and has a relatively good clinical application value.

The application provides a Mycoplasma hyopneumoniae antigen, a protein nanoparticle, a vaccine and a preparation method and application; the Mycoplasma hyopneumoniae antigen comprises SpyCatcher fusion proteins of ENOLASE, EF-TU, FBA, GAPDH, NOX, NFOR, MHP107, MHP597, MHP683, MHJ0461, MNUA, P28, P36, P42, P46, P65, P94, P97, P102, P110, P116, P146, P159, P216; and the protein nanoparticle of the Mycoplasma hyopneumoniae antigen is formed by self-assembly of the Mycoplasma hyopneumoniae antigen and an AP205-Spytag nanoparticle. The application provides 24 kinds of fusion proteins as Mycoplasma hyopneumoniae antigens, realizes connection of the fusion proteins and the nanoparticle, and further obtains a vaccine component for efficiently immunizing pigs against Mycoplasma hyopneumoniae.

This application discloses a method for determining the standard value of neuron-specific enolase (NSE) solution, belonging to the field of biotechnology. The determination method provided in this application includes characterizing the physicochemical properties of the NSE standard candidate solution, such as purity, molecular weight, secondary structure, and bioactivity; diluting and dispensing the NSE standard candidate solution; accurately determining the content of the NSE standard candidate solution and verifying its homogeneity and stability using isotope dilution mass spectrometry based on amino acid analysis and characteristic peptide analysis; and evaluating the uncertainty of the NSE solution standard value determination results. The determination method provided in this application has good reliability and accuracy, and the determination results are traceable to SI units (mol).

The present invention provides methods and uses for treating or preventing fibrosis and fibrotic diseases, including administering a composition containing an enolase inhibitor such as POMHEX.

Pharmaceutical compositions and methods for using boron-based ligands of enolases to treat cancer are disclosed. One such pharmaceutical composition includes a therapeutically effective amount of a ligand of enolase (1) having a general formula III or a pharmaceutically acceptable derivative thereof. The cancer can be a carcinoma, sarcoma, lymphoma, leukemia, or melanoma. The cancer can be prostate cancer.

To provide an estimation method for estimating the amount of marker proteins in the stratum corneum. [Solution] Identify one or more cell regions, stratified exfoliation regions, and single-cell regions in the stratum corneum image. A marker protein quantity estimation method that estimates the amount of marker proteins in the stratum corneum from stratum corneum images based on the correlation between the obtained stratum corneum parameters as explanatory variables and one of the following as the dependent variable: Enolase-1 quantity, FABP5 quantity, or Polyamine quantity.

A coupled tethered enzyme luminescence assay for measuring the amount of enzymatic activity of neural specific enolase in a liquid blood sample taken from a patient. The assay has a test well and a positive control well. The test well has a number of components including an inhibitor and a number of first tethered enzyme nanobots formed by tethering pyruvate kinase enzyme to silica nanoparticles, and a number of second enzyme nanobots formed by tethering luciferase molecules to silica nanoparticles for oriented immobilization of the tethered enzymes pyruvate and luciferase. The pyruvate kinase and luciferase enzymes have two differing types of affinity tags. One type of affinity tag facilitates extraction of enzymes from a liquid and another affinity tag for tethering to a silica nanoparticle. The positive control well includes the components of the test well and an added preset amount of enolase enzyme.